Progyny vs P3 Health Partners
Progyny and P3 Health Partners are similar in size: $1.29bn and $1.46bn of revenue in their latest fiscal years. Progyny grew faster (10.4% against -2.8%). Progyny kept more of each dollar of sales as profit: a net margin of 4.5% against -10.1%.
| Latest fiscal year | ProgynyPGNY, 2025 | P3 Health PartnersPIII, 2025 |
|---|---|---|
| Revenue | $1.29bn | $1.46bn |
| Revenue growth | 10.4% | -2.8% |
| Net income | $58.5m | −$148m |
| Operating margin | — | — |
| Net margin | 4.5% | -10.1% |
| Return on equity | 12.5% | — |
| Free cash flow | $192m | −$91.2m |
| Cash | $112m | $25.0m |
| Total debt | $0 | $337m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $81.7m | — |
| Employees | 1,000 | 320 |
| Market value | $2.25bn | $13.2m |
| Price vs our value range | Within our value range | — |
| Moat score | 43 (Weak) | — |
| Insider trades, 12 months | 1 buys, 25 sales | 0 buys, 3 sales |